Cleared Traditional

VX1+ (K223516) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K223516 · Volta Medical · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2023
Decision
60d
Days
Class 2
Risk

K223516 is an FDA 510(k) clearance for the VX1+. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Volta Medical (Marseille, FR). The FDA issued a Cleared decision on January 21, 2023 after a review of 60 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Volta Medical devices

Submission Details

510(k) Number K223516 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 22, 2022
Decision Date January 21, 2023
Days to Decision 60 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
65d faster than avg
Panel avg: 125d · This submission: 60d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K223516.
AcQMap® High Resolution Imaging and Mapping System
K230606 · Acutus Medical, Inc. · May 2023
CARTO® 3 EP Navigation System with CARTOSOUND™ 4D Version 7.4
K223733 · Biosense Webster, Inc. · Feb 2023
ZEUS System
K222389 · iRhythm Technologies, Inc. · Feb 2023
EndoPATx
K211557 · Itamar Medical , Ltd. · Dec 2022
EnSite™ X EP System TactiFlex™ Ablation Catheter, Sensor Enabled™, Software Upgrade
K223094 · Abbott Medical · Dec 2022
STAR Apollo Mapping System
K220786 · Rhythm Al, Ltd. · Dec 2022